Viking Therapeutics (VKTX) Free Cash Flow (2014 - 2026)

Viking Therapeutics has disclosed Free Cash Flow across 13 years of filings, most recently posting -$114.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$114.0 million, down 117.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$340.3 million (down 154.0% YoY), and the FY2025 annual result was -$278.7 million, down 217.45% from the prior year.
• Free Cash Flow came in at -$114.0 million for Q1 2026 at Viking Therapeutics, down from -$85.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$6.1 million in Q1 2024 to a low of -$114.0 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$22.0 million (2024), against an average of -$35.4 million.
• Across the five-year window, Free Cash Flow soared 75.11% in 2024 and plunged 753.13% in 2025, its largest moves.
• Viking Therapeutics' Free Cash Flow stood at -$10.9 million in 2022, then sank by 61.45% to -$17.6 million in 2023, then slumped by 76.76% to -$31.2 million in 2024, then plunged by 173.53% to -$85.3 million in 2025, then tumbled by 33.63% to -$114.0 million in 2026.
• The last three Free Cash Flow figures came in at -$114.0 million (Q1 2026), -$85.3 million (Q4 2025), and -$94.0 million (Q3 2025), per Business Quant data.